Impact of Ketoflex 12/3 Diet on Parkinson's Disease Symptoms: A Clinical Study

Medipol Health Group

Status: Completed

Conditions: Parkinson's Disease; Parkinson

Treatments: Behavioral: Ketoflex 12/3 Diet

Study type: Interventional

Funder types: Other

Identifiers

NCT06892418

PD23992

Details and patient eligibility

About

This study aims to investigate the effects of the Ketoflex 12/3 diet on motor and non-motor symptoms in patients with Parkinson's disease. Participants will follow the Ketoflex 12/3 dietary regimen, and their cognitive function, motor symptoms, sleep patterns, gastrointestinal health, and overall well-being will be assessed through standardized clinical scales. The study will help determine whether a plant-based ketogenic diet combined with intermittent fasting can have a beneficial impact on Parkinson's disease progression.

Full description

Parkinson's disease is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms. Emerging evidence suggests that dietary interventions, particularly ketogenic diets and intermittent fasting, may play a role in neuroprotection and symptom management. This study investigates the effects of the Ketoflex 12/3 diet, a plant-based ketogenic dietary approach combined with intermittent fasting, on Parkinson's disease progression. Clinical assessments will include Unified Parkinson's Disease Rating Scale (UPDRS), Mini-Mental State Examination (MMSE), depression and anxiety scales, sleep quality assessments, and gastrointestinal health evaluations. The study aims to provide new insights into the potential benefits of metabolic-based nutritional interventions in Parkinson's disease patients.

Enrollment: 40 patients

Sex: All

Ages: 40 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with Parkinson's disease
• Age between 40-85 years
• Native Turkish speakers
• Able to comply with the study protocol

Exclusion criteria

• History of alcohol or substance dependence
• Diagnosis of chronic renal failure
• Presence of neuromuscular disorders
• Having amalgam dental fillings and/or failure to remove them according to the SMART protocol
• Severe vitamin deficiencies that have not been corrected prior to the study

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

Ketoflex 12/3 Diet Group

Experimental group

Description:

A plant-based ketogenic diet combined with intermittent fasting (12/3)

Treatment:

Behavioral: Ketoflex 12/3 Diet

Control Group

No Intervention group